Notice Of Ablynx's Annual and Extraordinary General Meeting of Shareholders

Notice Of Ablynx's Annual and Extraordinary General Meeting of Shareholders

ID: 242906

(firmenpresse) - GHENT, BELGIUM -- (Marketwire) -- 03/26/13 -- (EURONEXT BRUSSELS: ABLX) today announced that its 2013 Annual and Extraordinary General meeting (AGM) will be held on Thursday, 25 April 2013 at 11:00h CET at its headquarters at Technologiepark 21, 9052 Ghent.

The convocation and proxy statement, agenda, and annual accounts 2012 will be directly and permanently available on the Company's website at from 26 March 2013.

The most important resolutions included in the agenda relate to the annual accounts 2012, the renewal of the authorised capital and the composition of the Board of Directors including the resignation of two non-executive Directors: Dr Roger Perlmutter who, to avoid conflicts of interest, is resigning from the Ablynx Board following his recent appointment at Merck & Co. as Executive Vice President and President of Merck Research Laboratories, and Geert Cauwenbergh who after five years will retire from the Ablynx Board.

is a biopharmaceutical company engaged in the discovery and development of , a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on .

press release in pdf:



Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e:

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:
Follow us on Twitter (at)AblynxABLX

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson




t: +44 207 920 2330
e:


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Trimel Announces Fourth Quarter and Year-End 2012 Financial Results Extenway Terminals: Hospitals in Gatineau and Hull Enter the 21st Century
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 26.03.2013 - 06:56 Uhr
Sprache: Deutsch
News-ID 242906
Anzahl Zeichen: 0

contact information:
Town:

GHENT, BELGIUM



Kategorie:

Healthcare



Diese Pressemitteilung wurde bisher 256 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Notice Of Ablynx's Annual and Extraordinary General Meeting of Shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z